Stocksigma LogoStocksigma Logo

Solara Reports Nil Deviation in Rights Issue Fund Utilization for Sep'26 Quarter

Solara Active Pharma Sciences reported zero deviation in the utilization of its ₹446.62 crore Rights Issue proceeds for the quarter ended 30th Sep'26

Solara Reports Nil Deviation in Rights Issue Fund Utilization for Sep'26 Quarter

Solara Active Pharma Sciences Ltd · Others (Uncategorized) · 16 Oct 2026, 9:33 pm

Solara Reports Nil Deviation in Rights Issue Fund Utilization for Sep'26 Quarter Solara Active Pharma Sciences reported zero deviation in the utilization of its ₹446.62 crore Rights Issue proceeds for the quarter ended 30th Sep'26. Total funds deployed reached ₹442.88 crore, including ₹334.71 crore fully utilized for debt repayment/prepayment and ₹105.17 crore spent toward general corporate purposes against an allocated ₹112.24 crore. During the quarter, ₹1.25 crore was deployed (₹1.10 crore for debt reduction, ₹0.15 crore for corporate purposes). Remaining unutilized funds include ₹0.14 crore in escrow and ₹3.60 crore in the monitoring account.

Original exchange filing (PDF)

More announcements from Solara Active Pharma Sciences Ltd

All Solara Active Pharma Sciences Ltd announcements